Sebastián Marciano, Leila Haddad, María V Reggiardo, Mirta Peralta, Cecilia Vistarini, Mónica Marino, Valeria I Descalzi, Claudia D'Amico, Sebastián Figueroa Escuti, Luis A Gaite, Roberto Perez Ravier, Cristina Longo, Silvia M Borzi, Omar A Galdame, Fernando Bessone, Hugo A Fainboim, Silvia Frías, Mariano Cartier, Adrián C Gadano
We report the first real-world prospective multicenter cohort study that evaluated the effectiveness and safety of original or generic sofosbuvir-based regimens in patients with chronic hepatitis C in Latin America. The main endpoints were assessment of sustained virological response and serious adverse events rates. A total of 321 patients with chronic hepatitis C treated with the following regimens were included: sofosbuvir plus daclatasvir for 12 (n = 34) or 24 (n = 135) weeks, sofosbuvir plus daclatasvir plus ribavirin for 12 (n = 84) or 24 (n = 56) weeks, or sofosbuvir plus ribavirin for 12 (n = 8) or 24 (n = 2) weeks...
May 2018: Journal of Medical Virology